Targeted Long-Acting Combination Antiretroviral Therapy Program (TLC-ART)
Targeted Long Acting HIV Therapy intended to clear virus in tissues and cells
Click here to visit the TLC-ART website.
Welcome to the University of Washington Targeted Long-acting Combination Anti-Retroviral Therapy (TLC-ART) program. We are scientists and physicians working toward developing a long acting and effective treatment to improve patient compliance and therapeutic outcomes. We hope to maximally suppress HIV and potentially contribute to a cure for AIDS.
Our researchers were the first to document pharmacological drug deficiency with HIV oral treatment. This has been linked to residual HIV in tissues. The TLC-ART program intends to overcome pharmacological drug deficiency by developing long-lasting, potent, antiretroviral therapies.
TLCART Program Coordinator
UWMC H-Wing rm H115
1959 NE Pacific St.
Health Sciences Building
Seattle, WA 98195
Phone: (206) 543-8769
Fax: (206) 543-3204
or e-mail email@example.com directly
Principle Investigator: Dr. Rodney JY Ho, PhD, FAAAS, FAAPS